In the trial, dubbed SYMMETRY, Efruxifermin demonstrated statistically significant cirrhosis reversal in patients with biopsy-confirmed compensated cirrhosis due to metabolic dysfunction-associated ...
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...
Analyst David Lebowitz of Citi maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a price target of $65.00.Invest ...
Bank of America upgraded Akero Therapeutics (NASDAQ:AKRO) on Thursday, citing what it called “game-changing” data the company ...
Shares of Akero Therapeutics ($AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, ...
Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...
Akero Therapeutics shares doubled to $55.64 in premarket trading after the company said it saw positive preliminary topline results from its Phase 2b study evaluating the efficacy and safety of its ...
(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...
Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback